MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with One Drop […]
One Drop, MannKind ink partnership for connected, inhaled diabetes tech
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform. The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech. […]
One Drop wins FDA nod, CE Mark for mobile blood glucose monitor
One Drop said today that it won 510(k) clearance from the FDA and CE Mark clearance for its One Drop | Chrome blood glucose monitoring system. The system is a part of One Drop | Premium, which the company touts as the 1st-ever monthly subscription service for affordable diabetes care. The subscription service includes unlimited blood glucose testing […]
MassDevice Network
@MassDevice
LinkedIn
YouTube